Key facts
- Aragen Life Sciences’s last known valuation is $1.4B (Aug 2025).
- It has raised $126.0M; the latest was Secondary Transaction - Private ($34.6M) in Aug 2025.
- Notable investors include Goldman Sachs Asset Management, Quadria Capital, Avendus Capital, SBI Life Insurance (Mumbai).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Aragen Life Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Aragen Life Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aragen Life Sciences
Operator of a life sciences research agency intended to serve the clinical research and development sectors. The company specializes in drug discovery, clinical development, contract manufacturing, formulation, and informatics services, enabling healthcare institutions to offer a broad spectrum of advanced healthcare products and services.
- Sector
- Healthcare
- HQ
- Hyderabad, India
- Founded
- 2001
- Employees
- 4,500
- Website
- aragen.com/
- Ownership
- Privately Held (backing)
Aragen Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aragen Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aragen Life Sciences in its N-PORT filings yet. We sweep new filings monthly.